← Al het nieuws

Laura van ’t Veer, PhD, Co-Inventor of MammaPrint, Honored with the PMWC Luminary Award

Laura van ’t Veer, Ph.D., co-founder of Agendia and developer of MammaPrint, the 70-gene risk of recurrence assay for breast cancer patients, will be recognized by Precision Medicine World Conference with the PMWC Luminary Award on January 21, 2020. This award recognizes those individuals who have made significant contributions to accelerate personalized medicine within the clinical setting.

As a Professor of Laboratory Medicine and Director of Applied Genomics at the University California San Francisco Helen Diller Family Comprehensive Cancer Center, Dr. van ’t Veer is committed to translational medicine that aims to leverage the genomic makeup of patient tumors and improve their clinical outcomes. Dr. van ’t Veer has authored more than 280 peer-reviewed scientific articles and is a co-inventor on 6 patents. In 2007, she received the European Society of Medical Oncology (ESMO) life-time achievement award for translational research in breast cancer, in 2014 the European Union Women Innovator Award, and in 2015 the EPO European Inventor award. Last year, she was recognized by 24/7 Wall Street as one of ’32 Amazing Women Inventors’. Currently, Dr. van ’t Veer serves as the Biomarker Committee Chair for the QLHC-sponsored I-SPY 2 adaptive clinical trial. By using genomic information obtained from participating patients, this trial seeks to elucidate how different tumors will respond to novel drug regimens thus improving patient outcomes.

Tal Bahar Co-founder and President, PMWC commented, “We are delighted to have Dr. van ’t Veer join the esteemed group of women leaders from academia and industry who have been honored for their contributions to precision medicine with this award through the years. We look forward to hear from her at the session Leveraging Real World Evidence to Drive Decisions.”

Source: Agendia (press release)